Granted Patent
B2
US 11,214,781 · App. 17/374,628 · Granted Jan 4, 2022
Engineered enzyme
Assignee:
Inscripta, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.
Claims (3)
1. A catalytically inactive CRISPR nuclease obtained from Eubacterium rectale MAD7 (dMAD7) having the amino acid sequence SEQ ID NO: 2 that retains the ability for sequence specific binding a bacteria genome.
2. The catalytically inactive CRISPR nuclease of claim 1 for sequence-specific binding a yeast genome.
3. The catalytically inactive CRISPR nuclease of claim 1 for sequence-specific binding an isolated mammalian cell genome.
Assignments (3)
MERGER AND CHANGE OF NAME
Recorded Sep 15, 2025
From: INSCRIPTA, INC.,; MANUS INSCRIPTA, INC.
To: MANUS INSCRIPTA, INC.
Reel/Frame 072252/0203 →
SECURITY INTEREST
Recorded Sep 8, 2025
From: MANUS BIO INC.; STO.PERU I LLC; STO.PERU II LLC; MANUS INTERMEDIATE INC.; MANUS INSCRIPTA, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 072836/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 1, 2021
From: KIM, JUHAN; MIJTS, BENJAMIN
To: INSCRIPTA, INC.
Reel/Frame 057359/0948 →
Continuity (6)
Continuation
16798315
· Feb 22, 2020
Provisional Application
62748668
· Oct 22, 2018
Cited By (1)